Myoinositol trispyrophosphate

Drug Profile

Myoinositol trispyrophosphate

Alternative Names: OXY 111A

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NormOxys
  • Developer NormOxys; University of Zurich
  • Class Cyclohexanes; Small molecules; Sugar alcohols
  • Mechanism of Action Haemoglobin modulators; Protein-serine-threonine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Cancer
  • No development reported Chronic heart failure; Obesity

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer in USA (IV, Infusion)
  • 28 Aug 2015 No development reported - Preclinical for Obesity in USA (IV)
  • 25 Aug 2015 No development reported - Phase-I for Chronic heart failure in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top